Live
When will the FDA reclassify BPC-157 to Category 1? — FDA - BPC
Starts:Mar 24, 2026, 2:00 PMEnds:Jan 1, 2027, 4:59 AM
AZRGMIKSHLMTNVGPLYPMU
Total volume
$93.9K
Largest spread
—
Outcomes
4
Platforms
1
Markets
1
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Before 2027 | 36.0%Kalshi | $19.1K | — | — | — | — | — | — | |
Before November | 7.0%Kalshi | $15.3K | — | — | — | — | — | — | |
Before 2027
36.0%Best · Kalshi$19.1K
Before November
7.0%Best · Kalshi$15.3K
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.